"We head into 2023 with cash on hand providing us with runway into 2024, and as we read out our key upcoming catalysts we expect to continue to allocate our capital carefully in order to preserve that runway and our optionality," said Brian Stephenson, Ph.D., CFA, Chief Financial Officer of BridgeBio. "We will also continue to look for ways to extend our runway by considering potential royalty monetizations and partnerships."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
- BridgeBio Pharma to Participate in February and March Investor Events
Questions or Comments about the article? Write to editor@tipranks.com